Preparation method of atorvastatin calcium intermediate

By using isopropanol and a specific catalyst in the preparation process of the atorvastatin calcium intermediate, an efficient condensation reaction is achieved, which solves the problems of low reaction efficiency and low product yield in the prior art, and reduces production costs. It also improves product quality and is suitable for industrial production.

CN118930526APending Publication Date: 2024-11-12SUZHOU DAWNRAYS PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410982214.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the existing preparation methods of atorvastatin calcium intermediates, the reaction efficiency is low, the product yield is not high, and the use of hydrocarbon mixed solvents leads to high reaction temperature, long time, complex post-processing, and high cost, which is not conducive to safety and environmental protection.

Method used

Isopropanol is used as the reaction solvent, combined with pivalic acid and catalysts (such as tetrabutylammonium fluoride and benzyltriethylammonium chloride) to undergo atmospheric distillation reaction at 80-82°C, cool down and crystallize, and simplify post-treatment Operation, reduce side reactions and by-products, and improve product quality.

Benefits of technology

It improves reaction efficiency, shortens reaction time, reduces production costs, simplifies post-processing operations, improves product quality, is suitable for industrial production, and is safer and more environmentally friendly.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930526A_ABST
    Figure CN118930526A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method of an atorvastatin calcium intermediate, which comprises the following steps: (1) adding isopropanol, pivalic acid and a side chain A9 into a reaction container, and uniformly mixing at 20-30 DEG C; (2) a mother nucleus M4 and a catalyst are added into the reaction liquid obtained in the step (1), a distillation reaction is carried out at the normal pressure at the temperature of 80-82 DEG C, and the catalyst is one or more of tetrabutylammonium fluoride, benzyltriethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium fluoride, benzyltriethylammonium chloride and tetrabutylammonium bromide; and (3) adding water into the reaction liquid in the step (2), cooling and crystallizing to obtain crystals, namely the atorvastatin calcium intermediate. According to the method, isopropanol with high safety is selected as a reaction solvent, the reaction efficiency of the condensation reaction of A9 and M4 is remarkably improved in the presence of pivalic acid and under the action of the selected catalyst, meanwhile, the post-treatment can be simplified, the yield is improved, the production cost is reduced, and the method is safer, more environmentally friendly and more suitable for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicines, and particularly relates to a method for preparing an atorvastatin calcium intermediate. Background Art

[0002] Atorvastatin calcium is a lipid-regulating drug that mainly acts on the liver. It can reduce the synthesis of cholesterol, increase the synthesis of low-density lipoprotein receptors, reduce the levels of total cholesterol, low-density lipoprotein and triglycerides, moderately reduce serum triglyceride levels and increase blood high-density lipoprotein levels.

[0003] The chemical name of atorvastatin calcium is (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanoate calcium trihydrate, and the structural formula is as follows:

[0004]

[0005] Atorvastatin calcium is prepared by deprotection, hydrolysis and salt formation of a key intermediate condensation product.

[0006] The intermediate condensate of atorvastatin calcium is the key intermediate condensate mentioned above, and its chemical name is (4R,6R)-2-[6-[2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl]-2,2-dimethyl-1,3-dioxane-4-yl]acetate tert-butyl ester, and its structural formula is as follows:

[0007]

[0008] The intermediate condensate of atorvastatin calcium is prepared by condensation of the parent core M4 and the side chain A9, and the reaction formula is as follows:

[0009]

[0010] The reaction efficiency, product yield, and safety and environmental protection of the existing preparation method of atorvastatin calcium intermediate need to be further improved, and the production cost needs to be reduced. For example, patent CN106938996A uses n-heptane / tetrahydrofuran mixed solvent to heat and reflux for 30-50h, concentrate to remove the mixed solvent, add ethanol / water for crystallization, and prepare condensation products with a yield of 80-85%. Patent CN106397296A uses cyclohexane, toluene, and cyclohexane / toluene mixed solvent to heat at 90-98°C for reflux for 20h, concentrate to remove the mixed solvent, add ethyl acetate to dissolve, wash with alkaline water, then wash with brine, dry, concentrate to remove ethyl acetate, steam with isopropanol three times, add isopropanol / water for crystallization, and prepare condensation products with a yield of 85-91%. CN104151286A uses a mixed solvent of toluene, xylene / heptane / tetrahydrofuran to heat at 90-110°C for reflux for 10h, cools down, washes with acid water, concentrates to remove the mixed solvent, adds ethanol / cyclohexane for crystallization, and prepares a condensate with a yield of 77-85%. Patent CN102344401A uses a mixed solvent of n-heptane / tetrahydrofuran to heat at 80-100°C for reflux and water separation reaction for 20-40h, concentrates to remove the mixed solvent, adds methanol for crystallization, and prepares a condensate with a yield of 92%. Patent CN102311376A uses a mixed solvent of n-heptane / tetrahydrofuran / toluene to heat at 85-92°C for reflux reaction for 20-24h, concentrates to remove the mixed solvent, adds ethyl acetate to dissolve, washes with alkaline water, then washes with brine, dries, concentrates to remove ethyl acetate, steams with isopropanol three times, adds isopropanol / water for crystallization, and prepares a condensate with a yield of 71-75%. Patent CN102127060A uses a toluene / n-heptane mixed solvent at 110-120°C constant temperature reflux water separation reaction for 12-14h, concentrates to remove the mixed solvent, adds ethyl acetate to dissolve, washes with alkaline water, then washes with brine, dries, decolorizes, concentrates to remove ethyl acetate, adds isopropanol to crystallize, and recrystallizes with isopropanol to prepare a condensate with a yield of 84.8-92.9% and a GC purity of 96.8-98.6%. Patent CN101429195A uses a mixed solvent of n-pentane / isopropyl ether, n-pentane / methyl tert-butyl ether, n-hexane / 2-methyltetrahydrofuran, and n-heptane / n-butyl ether to heat to 70-110°C reflux constant boiling water, concentrates to remove the mixed solvent, and recrystallizes with water / isopropanol to prepare a condensate with a yield of 70-75%. The above prior arts all use hydrocarbon mixed solvents as reaction solvents, with high reaction temperature, long reaction time, complex post-processing, high cost, and are not conducive to safety and environmental protection. Summary of the invention

[0011] The purpose of the present invention is to provide a method for preparing an atorvastatin calcium intermediate which has high reaction efficiency, simple post-treatment, low cost, safety and environmental protection and is suitable for industrial production.

[0012] In order to achieve the above object, the technical solution adopted by the present invention is:

[0013] A method for preparing an atorvastatin calcium intermediate, the preparation method comprising the following steps:

[0014] (1) adding isopropanol, pivalic acid and side chain A9 into a reaction vessel and mixing them at 20-30° C.;

[0015] (2) adding the mother nucleus M4 and a catalyst to the reaction solution of step (1), and performing a distillation reaction at 80-82° C. under normal pressure, wherein the catalyst is one or more of tetrabutylammonium fluoride, benzyltriethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium fluoride, benzyltriethylammonium chloride, and tetrabutylammonium bromide;

[0016] (3) adding water to the reaction solution of step (2), cooling and crystallizing, wherein the crystals are the atorvastatin calcium intermediate,

[0017] The structural formula of the side chain A9 is: The structural formula of the mother core M4 is: The structural formula of the atorvastatin calcium intermediate is:

[0018] The invention uses isopropanol as a reaction solvent, and while reacting under the action of a catalyst, water generated by the reaction is distilled off (during atmospheric distillation at 80-82° C., water generated by the reaction and isopropanol are distilled off azeotropically to promote the forward progress of the reaction). Compared with the existing condensation reaction using a hydrocarbon mixed solvent as a reaction solvent, the invention can lower the reaction temperature, greatly shorten the reaction time, reduce the occurrence of side reactions, reduce the amount of by-products, improve product quality, add water to crystallize under the same solvent system (the catalyst is retained in the mother liquor), simplify post-processing operations, and the solution can be recycled for reuse.

[0019] Preferably, in the step (2), while the atmospheric distillation reaction is being carried out, isopropanol is added dropwise to the reaction solution, and the dropping speed of the isopropanol is controlled to be consistent with the speed of the distillate.

[0020] Preferably, the ratio of isopropanol in step (1) and the mother core M4 in step (2) is (4-8) ml / g, for example, 4 ml / g, 4.5 ml / g, 5 ml / g, 5.5 ml / g, 6 ml / g, 6.5 ml / g, 7 ml / g, 7.5 ml / g, 8 ml / g.

[0021] Preferably, the molar ratio of the side chain A9 in step (1) to the mother core M4 in step (2) is (0.8-1.2):1, for example, 0.8:1, 0.85:1, 0.9:1, 0.95:1, 1.0:1, 1.05:1, 1.1:1, 1.15:1, 1.2:1.

[0022] Preferably, the molar ratio of pivalic acid in step (1) to the mother core M4 in step (2) is (0.8-1.2):1, for example, 0.8:1, 0.85:1, 0.9:1, 0.95:1, 1.0:1, 1.05:1, 1.1:1, 1.15:1, 1.2:1.

[0023] Preferably, in step (1), isopropanol and pivalic acid are first added to the reaction container, and then the side chain A9 is added dropwise, and the addition time is controlled to be 0.5 to 1 hour.

[0024] Preferably, the molar ratio of the catalyst in step (2) to the mother core M4 in step (2) is (0.01-0.2):1.

[0025] Further preferably, the molar ratio of the catalyst in step (2) to the mother core M4 in step (2) is (0.05-0.2):1.

[0026] Still further preferably, the molar ratio of the catalyst in step (2) to the mother core M4 in step (2) is (0.08-0.12):1, for example, 0.08:1, 0.09:1, 0.1:1, 0.11:1, 0.12:1.

[0027] Preferably, the reaction time of step (2) is 6 to 8 hours.

[0028] Preferably, the ratio of water in step (3) to the mother core M4 in step (2) is (2-4) ml / g, for example, 2 ml / g, 2.5 ml / g, 3 ml / g, 3.5 ml / g, 4 ml / g.

[0029] Preferably, the crystallization temperature is 0-10°C.

[0030] More preferably, the crystallization temperature is 4-10°C.

[0031] Still more preferably, the crystallization temperature is 4-8°C.

[0032] More preferably, the crystallization temperature is 4-6°C.

[0033] Preferably, the crystallization time is 1 to 12 hours.

[0034] More preferably, the crystallization time is 5 to 12 hours.

[0035] Still more preferably, the crystallization time is 8 to 12 hours.

[0036] Preferably, the step (3) comprises: cooling the reaction solution of step (2) to 0-10°C, stirring and crystallizing at 0-10°C for 1-12 hours, filtering, slurrying the filter cake with a 65-75% isopropanol aqueous solution, draining, and vacuum drying the wet product at 60-70°C to constant weight.

[0037] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art:

[0038] The preparation method of the invention selects isopropanol with high safety as a reaction solvent, reduces the reaction temperature of the condensation reaction of the side chain A9 and the mother core M4 under the condition of the presence of pivalic acid and the action of a selected catalyst, shortens the reaction time, improves product quality and yield, has simple post-processing, and the solvent can be recycled and reused, thereby reducing production costs, being safe and environmentally friendly, and being suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 is the HPLC spectrum of the condensation product of Example 1;

[0040] Figure 2 is the HPLC spectrum of the condensation product of Example 2;

[0041] Figure 3 is the HPLC spectrum of the condensation product of Example 3;

[0042] Figure 4 is the system suitability HPLC spectrum of Example 1 (showing the peak of atorvastatin calcium intermediate standard);

[0043] Figure 5 is the blank HPLC spectrum of Example 1 (showing the solvent peak); DETAILED DESCRIPTION

[0044] In the prior art, atorvastatin calcium intermediates use hydrocarbon mixed solvents as reaction solvents, which have high reaction temperatures, long reaction times, and complex post-processing, resulting in low reaction efficiency and high components, which is not conducive to industrial production. After extensive research, the inventors unexpectedly discovered that using a single alcohol solvent, isopropanol, as a reaction solvent, in the presence of pivalic acid and under the action of a selected catalyst, the reaction efficiency of the condensation reaction of the side chain A9 and the parent nucleus M4 is significantly improved, and the post-processing can be simplified, while the product yield is increased and the production cost is reduced, which is safer, more environmentally friendly, and more suitable for industrial production, thereby proposing a method for preparing atorvastatin calcium intermediates of the present invention:

[0045] (1) adding isopropanol, pivalic acid and side chain A9 into a reaction vessel and mixing them uniformly at 20-30° C.;

[0046] (2) adding the mother nucleus M4 and a catalyst to the reaction solution of step (1), and performing a distillation reaction at 80-82° C. under normal pressure, wherein the catalyst is one or more of tetrabutylammonium fluoride, benzyltriethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium fluoride, benzyltriethylammonium chloride, and tetrabutylammonium bromide;

[0047] (3) adding water to the reaction solution of step (2), cooling and crystallizing to obtain the atorvastatin calcium intermediate.

[0048] The present invention is further described below in conjunction with the examples. However, the present invention is not limited to the following examples. The implementation conditions used in the examples can be further adjusted according to the different requirements of specific use, and the implementation conditions not specified are conventional conditions in the industry. The technical features involved in each embodiment of the present invention can be combined with each other as long as they do not conflict with each other.

[0049] In the present invention, the room temperature is 25±5°C.

[0050] In the following examples and comparative examples, the raw materials used were all commercially available with a purity greater than 99%. The supplier of the side chain A9 was Jiangsu Alpha Pharmaceutical Co., Ltd. with a purity of 99.0%; the supplier of the core M4 was Jiangsu Alpha Pharmaceutical Co., Ltd. with a purity of 99.8%.

[0051] In the following examples and comparative examples, unless otherwise specified, "%" refers to mass percentage.

[0052] In the following examples and comparative examples, the reaction formula of the reaction of M4 and A9 is as follows:

[0053]

[0054] Example 1

[0055] Add 200 ml of isopropanol (5.9 V / W) and 9.3 g of pivalic acid (0.091 mol, 1.1 eq) to a 500 ml flask and stir to dissolve; slowly add 25.0 g of A9 (0.091 mol, 1.1 eq) at room temperature while stirring for 0.5 hours. After the addition is completed, continue stirring for 15 minutes until the mixture is uniformly stirred; add 34.0 g of M4 (0.081 mol, 1 eq), 2.1 g tetrabutylammonium fluoride (0.0008 mol, 0.1 eq); heated to 80°C with stirring and distilled at normal pressure for 7 hours, and isopropanol was slowly added dropwise simultaneously, and the dropping speed was controlled to be consistent with the speed of the distillate. TLC (developing solvent is n-hexane / ethyl acetate = 5 / 1) detection showed that the M4 spot disappeared; cooled to 70°C, and 100 ml of purified water was slowly added; cooled slowly to 5°C (about 4 hours to 5°C) under stirring, and stirred and crystallized at 5°C for 8 hours; filtered, the filter cake was slurried three times with 100 ml of 70% isopropanol aqueous solution prepared in advance, and dried, and the wet product was vacuum dried at 65°C to constant weight to obtain 50.4 g of white crystalline powder, with a yield of 95.0%. The peak time of the product detected by HPLC was 23.903 min, which was consistent with the peak time of the atorvastatin calcium intermediate standard ( Figure 4 , 23.915min) are basically the same, the purity is 99.68%, and the content of individual impurities is less than 0.10% ( Figure 1 ).

[0056] Example 2

[0057] Add 200 ml of isopropanol (5.9 V / W) and 9.3 g of pivalic acid (0.091 mol, 1.1 eq) to a 500 ml flask and stir to dissolve; slowly add 25.0 g of A9 (0.091 mol, 1.1 eq) under stirring at room temperature for 0.5 hours. After the addition is completed, continue stirring for 15 minutes until the mixture is uniformly stirred; add 34.0 g of M4 (0.081 mol, 1 eq), 1.8 g benzyltriethylammonium chloride (0.0008 mol, 0.1 eq); heated to 80°C with stirring and distilled at normal pressure for 7 hours, and isopropanol was slowly added simultaneously, and the dropping speed was controlled to be consistent with the speed of the distillate. TLC (developing solvent is n-hexane / ethyl acetate = 5 / 1) detection showed that the M4 spot disappeared; cooled to 70°C, and 100 ml of purified water was slowly added; cooled slowly to 5°C (about 4 hours to 5°C) under stirring, and stirred and crystallized at 5°C for 8 hours; filtered, the filter cake was slurried three times with 100 ml of 70% isopropanol aqueous solution prepared in advance, and dried, and the wet product was vacuum dried at 65°C to constant weight to obtain 50.2 g of white crystalline powder, with a yield of 94.5%. The peak time of the product detected by HPLC was 23.907 min, which was consistent with the peak time of the atorvastatin calcium intermediate standard ( Figure 4, 23.915min) are basically the same, the purity is 99.67%, and the content of individual impurities is less than 0.10% ( Figure 2 ).

[0058] Example 3

[0059] Add 200 ml of isopropanol (5.9 V / W) and 9.3 g of pivalic acid (0.091 mol, 1.1 eq) to a 500 ml flask and stir to dissolve; slowly add 25.0 g of A9 (0.091 mol, 1.1 eq) under stirring at room temperature and stir evenly. The addition time is 0.5 hours. After the addition is completed, continue stirring for 15 minutes until the mixture is evenly stirred; add 34.0 g of M4 (0.081 mol, 1 eq), 2.6 g tetrabutylammonium bromide (0.0008 mol, 0.1 eq); stirring, heating to 80 ° C, distilling at normal pressure for 7 hours, slowly adding isopropanol, controlling the dropping speed to be consistent with the speed of the distillate, TLC (developing solvent is n-hexane / ethyl acetate = 5 / 1) detection shows that the M4 spot disappears; cooling to 70 ° C, slowly adding 100 ml of purified water; slowly cooling to 5 ° C (about 4 hours to 5 ° C) under stirring, keeping at 5 ° C and stirring for crystallization for 8 hours; filtering, the filter cake was slurried three times with 100 ml of 70% isopropanol aqueous solution prepared in advance, drained, and the wet product was vacuum dried at 60-70 ° C to constant weight to obtain 49.9 g of white crystalline powder, with a yield of 94.0%, and the peak time of the product detected by HPLC was 23.903 min, which was consistent with the peak time of the atorvastatin calcium intermediate standard ( Figure 4 , 23.915min) are basically the same, the purity is 99.55%, and the content of individual impurities is less than 0.10% ( Figure 3 ).

[0060] Comparative Example 1

[0061] Add 200 ml cyclohexane (5.9 V / W) and 9.3 g pivalic acid (0.091 mol, 1.1 eq) to a 500 ml flask and stir to dissolve; slowly add 25.0 g A9 (0.091 mol, 1.1 eq) under stirring at room temperature for 0.5 hours. After the addition is completed, continue stirring for 15 minutes until the mixture is uniformly stirred; add 34.0 g M4 (0.081 mol, 1 eq), 2.1 g tetrabutylammonium fluoride (0.0008 mol, 0.1 eq); stirring, heating and reflux reaction for 30 hours, TLC (developing solvent is n-hexane / ethyl acetate = 5 / 1) detection shows that the M4 spot disappears; slowly distill under reduced pressure (-0.08 MPa, 80°C) until there is no obvious fraction; add 200 ml of isopropanol, heat to about 70°C, stir to dissolve; slowly add 100 ml of purified water; slowly cool to 5°C (about 4 hours to 5°C) under stirring, keep warm at 5°C and continue stirring and crystallizing for 8 hours; filter, the filter cake is slurried three times with 100 ml of 70% isopropanol aqueous solution prepared in advance, drained, and the wet product is vacuum dried at 65°C to constant weight to obtain 45.6 g of white crystalline powder, with a yield of 86.0%.

[0062] Comparative Example 2

[0063] Add 200 ml of n-heptane (5.9 V / W) and 9.3 g of pivalic acid (0.091 mol, 1.1 eq) to a 500 ml flask and stir to dissolve; slowly add 25.0 g of A9 (0.091 mol, 1.1 eq) under stirring at room temperature for 0.5 hours. After the addition is completed, continue stirring for 15 minutes until the mixture is uniformly stirred; add 34.0 g of M4 (0.081 mol, 1 eq), 2.1 g tetrabutylammonium fluoride (0.0008 mol, 0.1 eq); stirring, heating and reflux reaction for 30 hours, TLC (developing solvent is n-hexane / ethyl acetate = 5 / 1) detection shows that the M4 spot disappears; slowly distill under reduced pressure (-0.08 MPa, 80°C) until there is no obvious fraction; add 200 ml of isopropanol, heat to about 70°C, stir to dissolve; slowly add 100 ml of purified water; slowly cool to 5°C (about 4 hours to 5°C) under stirring, keep warm at 5°C and continue stirring and crystallizing for 8 hours; filter, the filter cake is slurried three times with 100 ml of 70% isopropanol aqueous solution prepared in advance, drained, and the wet product is vacuum dried at 60-70°C to constant weight to obtain 40.8 g of white crystalline powder, with a yield of 77.0%.

[0064] Comparative Example 3

[0065] Add 200 ml toluene (5.9 V / W) and 9.3 g pivalic acid (0.091 mol, 1.1 eq) to a 500 ml flask and stir to dissolve; slowly add 25.0 g A9 (0.091 mol, 1.1 eq) under stirring at room temperature for 0.5 hours. After the addition is completed, continue stirring for 15 minutes until the mixture is uniformly stirred; add 34.0 g M4 (0.081 mol, 1 eq), 2.1 g tetrabutylammonium fluoride (0.0008 mol, 0.1 eq); stirring, heating and reflux reaction for 30 hours, TLC (developing solvent is n-hexane / ethyl acetate = 5 / 1) detection shows that the M4 spot disappears; slowly distill under reduced pressure (-0.08 MPa, 80°C) until there is no obvious fraction; add 200 ml of isopropanol, heat to about 70°C, stir to dissolve; slowly add 100 ml of purified water; slowly cool to 5°C (about 4 hours to 5°C) under stirring, keep warm at 5°C and continue stirring and crystallizing for 8 hours; filter, the filter cake is slurried three times with 100 ml of 70% isopropanol aqueous solution prepared in advance, drained, and the wet product is vacuum dried at 60-70°C to constant weight to obtain 31.8 g of white crystalline powder, with a yield of 60.0%.

[0066] The time required for the reaction of Comparative Examples 1 to 3 until the TLC detection shows that the M4 spot disappears is significantly longer than that of Examples 1 to 3. After the reaction is complete in Comparative Example 1, the reaction solvent and the water generated by the reaction need to be removed by vacuum distillation. After the solvent is replaced with isopropanol, the same post-treatment process as in Examples 1 to 3 is adopted, and the product yield is lower than that of Examples 1 to 3. The possible reason for this is that it is difficult to completely remove the reaction solvent when the reaction solvent and the generated water in the reaction solution are removed by vacuum distillation. In actual operation, after Comparative Examples 1 to 3 are slowly decompressed until there is no obvious fraction, a small amount of reaction solvent remains. In the subsequent crystallization step, the residual reaction solvent may affect the crystallization effect to varying degrees. Moreover, the TLC detection of the M4 spot can only roughly determine whether the M4 reaction is complete. In fact, after the M4 content in the reaction solution is less than 5%, the M4 spot cannot be detected, and it may not be truly completely reacted. This may also be one of the reasons why the product yield of Comparative Examples 1 to 3 is lower than that of Examples 1 to 3.

[0067] The above detailed description of the present invention is intended to enable persons familiar with the art to understand the contents of the present invention and implement them. It does not limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing an atorvastatin calcium intermediate, characterized in that: The preparation method comprises the following steps: (1) adding isopropanol, pivalic acid and side chain A9 into a reaction vessel and mixing them uniformly at 20-30° C.; (2) adding the mother nucleus M4 and a catalyst to the reaction solution of step (1), and performing a distillation reaction at 80-82° C. under normal pressure, wherein the catalyst is one or more of tetrabutylammonium fluoride, benzyltriethylammonium chloride, tetrabutylammonium bromide, tetrabutylammonium fluoride, benzyltriethylammonium chloride, and tetrabutylammonium bromide; (3) adding water to the reaction solution of step (2), cooling and crystallizing, wherein the crystals are the atorvastatin calcium intermediate, The structural formula of the side chain A9 is: The structural formula of the mother core M4 is: The structural formula of the atorvastatin calcium intermediate is:

2. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: In the step (2), while the atmospheric distillation reaction is being carried out, isopropanol is added dropwise to the reaction solution, and the dropping speed of the isopropanol is controlled to be consistent with the speed of the distillate.

3. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The ratio of isopropanol in step (1) to the mother core M4 in step (2) is (4-8) ml / g.

4. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The molar ratio of the side chain A9 in step (1) to the mother core M4 in step (2) is (0.8-1.2):1; And / or, the molar ratio of the pivalic acid in step (1) to the mother core M4 in step (2) is (0.8-1.2):

1.

5. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: In the step (1), isopropanol and pivalic acid are first added to the reaction container, and then the side chain A9 is added dropwise, and the dropping time is controlled to be 0.5 to 1 hour.

6. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The molar ratio of the catalyst in step (2) to the mother core M4 in step (2) is (0.01-0.2):

1.

7. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The reaction time of step (2) is 6 to 8 hours.

8. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The ratio of water in step (3) to the mother core M4 in step (2) is (2-4) ml / g.

9. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The crystallization temperature is 0 to 10° C., and the crystallization time is 1 to 12 hours.

10. The method for preparing an atorvastatin calcium intermediate according to claim 1, characterized in that: The step (3) comprises: cooling the reaction solution of step (2) to 0-10° C., stirring and crystallizing at 0-10° C. for 1-12 hours, filtering, slurrying the filter cake with a 65-75% isopropanol aqueous solution, draining, and vacuum drying the wet product at 60-70° C. to constant weight.